The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study

阿帕蒂尼 医学 肝细胞癌 内科学 联合疗法 胃肠病学 不利影响 肿瘤科 酪氨酸激酶抑制剂 实体瘤疗效评价标准 肝癌 无进展生存期 癌症 化疗 临床研究阶段
作者
Zeran Yang,Guang Chen,Ye Cui,Xiao Guo-wen,Ting Su,Jianan Yu,Zhiyuan Zhang,Yanjing Han,Kai-Lan Yang,Long Jin
出处
期刊:Cancer Biology & Therapy [Informa]
卷期号:20 (3): 321-327 被引量:34
标识
DOI:10.1080/15384047.2018.1529099
摘要

As a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor (VEGFR2-TKI), apatinib has a certain anti-tumor effect for a variety of solid tumors. The present study evaluates its efficacy and safety in advanced hepatocellular carcinoma (HCC). In this study, 47 patients with advanced HCC were included. TACE monotherapy group included 22 patients that responded to TACE, while the group that received TACE and apatinib included 25 patients that progressed on TACE and were able to receive apatinib off label. Median overall survival (OS) was significantly improved in the apatinib plus TACE group compared with the TACE group. Similarly, apatinib in combination with TACE significantly prolonged median progression-free survival (PFS) compared with TACE monotherapy. Furthermore, there was a significant difference between combination therapy and monotherapy in both Barcelona clinic liver cancer (BCLC) B and BCLC C group. The combination therapy had a dramatic effect on OS and PFS for patients at both BCLC B and BCLC C level. The most common clinically adverse events of apatinib plus TACE group were fatigue, weight loss, hypertension, hand-foot syndrome and anorexia, which were manageable and tolerable. The efficacy analysis showed that there was no significant association of survival benefit with age, gender, Eastern Cooperative Oncology Group (ECOG) performance status, hypertension and hand-foot syndrome. Patients with macrovascular invasion and extrahepatic invasion showed worse survival benefits. In conclusion, apatinib combined with TACE revealed certain survival benefits for HCC patients who experienced progression following TACE, which can provide a promising strategy for HCC treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
兔BF完成签到,获得积分10
4秒前
雪落完成签到,获得积分10
5秒前
7秒前
12秒前
wyl完成签到,获得积分10
12秒前
脑洞疼应助Suibobobo采纳,获得10
13秒前
keyanxiaozi发布了新的文献求助10
15秒前
背后的小白菜完成签到,获得积分10
15秒前
你今天学了多少完成签到 ,获得积分10
15秒前
科研通AI2S应助勤劳滑板采纳,获得10
21秒前
ZCJ123发布了新的文献求助30
24秒前
爱吃果果的泡泡完成签到,获得积分10
27秒前
LiS发布了新的文献求助10
29秒前
心凉完成签到,获得积分10
29秒前
spinning完成签到,获得积分10
30秒前
Akim应助俺爱SCI采纳,获得10
31秒前
乐乐应助czy采纳,获得10
32秒前
YANA完成签到,获得积分10
35秒前
劲秉应助LiS采纳,获得10
38秒前
TTTTTOTOT完成签到,获得积分10
39秒前
小广完成签到,获得积分10
40秒前
自然冬易完成签到,获得积分10
42秒前
迷人寒梦完成签到 ,获得积分10
42秒前
43秒前
华仔应助keyanxiaozi采纳,获得10
45秒前
李秋秋发布了新的文献求助10
46秒前
清脆的大开完成签到,获得积分10
48秒前
wenwen关注了科研通微信公众号
50秒前
50秒前
科研通AI2S应助科研通管家采纳,获得30
50秒前
完美世界应助科研通管家采纳,获得10
50秒前
传奇3应助科研通管家采纳,获得10
51秒前
orixero应助科研通管家采纳,获得10
51秒前
金刚经应助科研通管家采纳,获得10
51秒前
科研通AI2S应助科研通管家采纳,获得10
51秒前
小二郎应助科研通管家采纳,获得10
51秒前
思源应助科研通管家采纳,获得10
51秒前
Owen应助科研通管家采纳,获得10
51秒前
Tin发布了新的文献求助10
52秒前
仁爱忆山完成签到 ,获得积分10
52秒前
高分求助中
Spray / Wall-interaction Modelling by Dimensionless Data Analysis 2000
ALA生合成不全マウスでの糖代謝異常の分子機構解析 520
安全防范技术与工程 500
Mathematics and Finite Element Discretizations of Incompressible Navier—Stokes Flows 500
2-Acetyl-1-pyrroline: an important aroma component of cooked rice 500
A real-time energy management strategy based on fuzzy control and ECMS for PHEVs 400
2024 Medicinal Chemistry Reviews 400
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3190614
求助须知:如何正确求助?哪些是违规求助? 2839837
关于积分的说明 8025743
捐赠科研通 2502803
什么是DOI,文献DOI怎么找? 1336660
科研通“疑难数据库(出版商)”最低求助积分说明 637899
邀请新用户注册赠送积分活动 606105